CSL has surged 35.5% since early June, clearing key moving averages despite little fundamental change. Is the battered biotech giant staging a comeback?

Mr Wilson’s interest rate outlook is central to his broader call. Falling energy prices, fading tariff-related inflation and ...

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

These stocks have jumped in the double- and triple-digits.

Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...

The stock was up 39% to $2.25 in late Tuesday morning trading. The shares are now down less than 1% in the past 52 weeks. Farokhzad, who is also the biotechnology company's chair, made the unsolicited ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...

Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. AVE has ...

Hyperscalers may benefit as chip stocks struggle, according to Morgan Stanley strategists. The once-hot semiconductor trade has seen a cooling in the last couple of weeks, which is not only likely to ...

Hyperscalers may benefit as chip stocks struggle, according to Morgan Stanley strategists. The once-hot semiconductor trade has seen a cooling in the last couple of weeks, which is not only likely to ...